Lonza launches nebula absorbance reader for streamlined Endotoxin and Pyrogen testing

The instrument is fully integrated with Lonza’s latest WinKQCLSoftware to enable data integrity compliance, streamline training, and reduce validation burden

Govt. passes National Dental Commission Bill, 2023

The National Dental Commission Act 2023, will introduce a groundbreaking regulatory framework by establishing the National Dental Commission

USFDA concludes inspection at Solara's Cuddalore facility with Zero 483 inspectional observations

Dabur India posts Q1 FY24 PAT at Rs. 463.88 Cr

The company has posted net profit of Rs. 463.88 crores for the period ended June 30, 2023

Zydus receives USFDA's final approval for Indomethacin Suppository with competitive generic therapy designation

Zydus' Indomethacin suppositories also been granted 180-day CGT exclusivity to market this product.

Thyrocare Technologies posts Q1 FY24 PAT at Rs. 17.30 Cr

The company has reported total income of Rs. 135.87 crores during the period ended June 30, 2023

Venus Remedies oncology wing product registrations go up to 506 with marketing approvals from 4 more countries

The company has secured 506 marketing approvals for its oncology products across 76 countries.

Concord Biotech’s IPO to open on 4th August, 2023

The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.

Jemperli plus chemotherapy approved in the US as the first new frontline treatment option for dMMR/MSI-H primary advanced or recurrent endometrial cancer

Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy

Biogen to acquire Reata Pharmaceuticals

Proposed acquisition represents meaningful step forward in Biogen’s strategy for sustainable growth